Bausch + Lomb (BLCO) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic transformation, vision, and innovation

• Leadership and cultural shifts have fostered urgency, accountability, and innovation, accelerating decision-making and product development.

• Technology modernization and accelerated R&D have led to a record number of patents, with 59 new applications in 2025, supporting durable growth.

• Innovation is embedded company-wide, focusing on meaningful products and platforms that address clinical and market needs.

• Strategy targets 5–7% constant currency revenue CAGR from 2025–2028, with all business segments contributing.

• Focus on disruptive innovation and elevating standard of care across all business lines.

Product pipeline and upcoming launches

• Major launches planned between 2026–2031 include PreserVision AREDS 3, Blink Triple Care drops, LUMIFY Lux, bioactive and myopia control lenses, and next-gen surgical devices.

• Pharmaceutical pipeline features dual-action dry eye drops, glaucoma asset with neuroprotective effects, and AMD/geographic atrophy agents with $3.9B peak sales potential.

• Projected total peak sales from pipeline products estimated at ~$7B, with launches staggered by product.

• Contact lens growth driven by new daily offerings, bioactive lens (2028), and SiHy products (2029), with launches in 60+ countries.

• Surgical business expects growth from premium IOLs, Elios MIGS laser, Solera femtosecond laser, and Cynova platform, targeting up to $1B peak sales from new products by 2028.

Market leadership and product expansion

• Maintains #1 global OTC eye health position, with brands like PreserVision, Ocuvite, and Lumify Luxe driving growth.

• Consumer, contact lens, pharmaceuticals, and surgical segments all forecast 5–7% CAGR through 2028.

• Contact lens segment outperforms market, targeting multifocal, astigmatism, and myopia control.

• Expanding in premium surgical categories with new IOLs, lasers, and combo devices, targeting peak sales up to $450M per product.

• Ongoing clinical studies and regulatory submissions support robust innovation pipeline.